The invention relates to a pharmaceutical composition comprising a
monoamine neurotransmitter re-uptake inhibitor comprising a
2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically
acceptable salt, solvate, or physiologically functional derivative
thereof, and at least one acetylcholinesterase inhibitor or a
pharmaceutically acceptable salt, solvate, or physiologically functional
derivative thereof, and a pharmaceutically acceptable carrier or
excipient, and optionally one or more other therapeutic ingredients.
